Home

Articles from Leyden Laboratories B.V.

Leyden Labs Publishes New Data Confirming Potential of Intranasal Antibody Approach
Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced the publication of new findings that showcase the advantages of intranasal administration of monoclonal antibodies over systemic administration for protection against airborne viruses.
By Leyden Laboratories B.V. · Via Business Wire · April 8, 2025
Leyden Labs Raises $70M to Advance its Intranasal Antibody Programs to Protect against Influenza and other Viruses
Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, such as influenza and coronaviruses.
By Leyden Laboratories B.V. · Via Business Wire · January 9, 2025
Leyden Labs Appoints Jintanat Ananworanich, M.D., Ph.D., as Chief Medical Officer
Leyden Laboratories B.V., (the "Company" or "Leyden Labs"), a biotechnology company working to free people from the threat of respiratory viruses by boosting mucosal immunity, today announced the appointment of Jintanat Ananworanich, M.D., Ph.D., as chief medical officer. Dr. Ananworanich, a physician with global experience fighting infectious disease, will oversee clinical development of Leyden Labs’ portfolio of intranasal product candidates.
By Leyden Laboratories B.V. · Via Business Wire · September 12, 2024
Leyden Labs’ Intranasal PanFlu Antibody Enters the Clinic
Leyden Laboratories B.V., (the “Company” or “Leyden Labs”) announced today the dosing of the first Phase 1 healthy volunteer cohort with a nasal spray containing PanFlu candidate CR9114. CR9114 is a universal anti-hemagglutinin stem human antibody which has been shown to provide broad protection in animal studies against influenza infection and disease.
By Leyden Laboratories B.V. · Via Business Wire · April 19, 2023